Relation between brain natriuretic peptide and delayed cerebral ischemia in patients with aneurysmalsubarachnoid hemorrhage.


Journal

Clinical neurology and neurosurgery
ISSN: 1872-6968
Titre abrégé: Clin Neurol Neurosurg
Pays: Netherlands
ID NLM: 7502039

Informations de publication

Date de publication:
12 2021
Historique:
received: 01 09 2021
revised: 31 10 2021
accepted: 06 11 2021
pubmed: 28 11 2021
medline: 23 3 2022
entrez: 27 11 2021
Statut: ppublish

Résumé

Brain natriuretic peptide (BNP), often used to evaluate degree of heart failure, has been implicated in fluid dysregulation and inflammation in critically-ill patients. Twenty to 30% of patients with aneurysmal subarachnoid hemorrhage (aSAH) will develop some degree of neurogenic stress cardiomyopathy (NSC) and in turn elevation of BNP levels. We sought to explore the association between BNP levels and development of delayed cerebral ischemia (DCI) in patients with aSAH. We retrospectively evaluated the records of 149 patients admitted to the Neurological Intensive Care Unit between 2006 and 2015 and enrolled in an existing prospectively maintained aSAH database. Demographic data, treatment and outcomes, and BNP levels at admission and throughout the hospital admission were noted. Of the 149 patients included in the analysis, 79 developed DCI during their hospital course. We found a statistically significant association between DCI and the highest recorded BNP (OR 1.001, 95% CI-1.001-1.002, p = 0.002). The ROC curve analysis for DCI based on BNP showed that the highest BNP level during hospital admission (AUC 0.78) was the strongest predictor of DCI compared to the change in BNP over time (AUC 0.776) or the admission BNP (AUC 0.632). Our study shows that DCI is associated not only with higher baseline BNP values (admission BNP), but also with the highest BNP level attained during the hospital course and the rapidity of change or increase in BNP over time. Prospective studies are needed to evaluate whether routine measurement of BNP may help identify SAH patients at high risk of DCI.

Sections du résumé

BACKGROUND
Brain natriuretic peptide (BNP), often used to evaluate degree of heart failure, has been implicated in fluid dysregulation and inflammation in critically-ill patients. Twenty to 30% of patients with aneurysmal subarachnoid hemorrhage (aSAH) will develop some degree of neurogenic stress cardiomyopathy (NSC) and in turn elevation of BNP levels. We sought to explore the association between BNP levels and development of delayed cerebral ischemia (DCI) in patients with aSAH.
METHODS
We retrospectively evaluated the records of 149 patients admitted to the Neurological Intensive Care Unit between 2006 and 2015 and enrolled in an existing prospectively maintained aSAH database. Demographic data, treatment and outcomes, and BNP levels at admission and throughout the hospital admission were noted.
RESULTS
Of the 149 patients included in the analysis, 79 developed DCI during their hospital course. We found a statistically significant association between DCI and the highest recorded BNP (OR 1.001, 95% CI-1.001-1.002, p = 0.002). The ROC curve analysis for DCI based on BNP showed that the highest BNP level during hospital admission (AUC 0.78) was the strongest predictor of DCI compared to the change in BNP over time (AUC 0.776) or the admission BNP (AUC 0.632).
CONCLUSION
Our study shows that DCI is associated not only with higher baseline BNP values (admission BNP), but also with the highest BNP level attained during the hospital course and the rapidity of change or increase in BNP over time. Prospective studies are needed to evaluate whether routine measurement of BNP may help identify SAH patients at high risk of DCI.

Identifiants

pubmed: 34837820
pii: S0303-8467(21)00560-6
doi: 10.1016/j.clineuro.2021.107031
pii:
doi:

Substances chimiques

Natriuretic Peptide, Brain 114471-18-0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

107031

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Gurmeen Kaur (G)

Department of Neurosurgery and Neurology, Westchester Medical Center at New York Medical College, Valhalla, NY, USA.

Nitesh Damodara (N)

Department of Neurosurgery and Neurology, Westchester Medical Center at New York Medical College, Valhalla, NY, USA.

Eric Feldstein (E)

Department of Neurosurgery and Neurology, Westchester Medical Center at New York Medical College, Valhalla, NY, USA.

Jose Dominguez (J)

Department of Neurosurgery and Neurology, Westchester Medical Center at New York Medical College, Valhalla, NY, USA.

Kristen T Huang (KT)

Department of Neurosurgery and Neurology, Westchester Medical Center at New York Medical College, Valhalla, NY, USA.

Jonathan V Ogulnick (JV)

Department of Neurosurgery and Neurology, Westchester Medical Center at New York Medical College, Valhalla, NY, USA.

Rolla Nuoman (R)

Department of Neurology, Maria Fareri Children's Hospital - Westchester Medical Center at New York Medical College, Valhalla, NY, USA.

Priyank Khandelwal (P)

Department of Neurosurgery and Neurology, Rutgers New Jersey Medical School, Newark, NJ, USA.

Mohammad El-Ghanem (M)

Department of Neurology and Medical Imaging, University of Arizona, Banner University Medical Center, Tucson, AZ, USA.

Gaurav Gupta (G)

Department of Neurosurgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

Stephan A Mayer (SA)

Department of Neurosurgery and Neurology, Westchester Medical Center at New York Medical College, Valhalla, NY, USA.

Krishna Amuluru (K)

Goodman Campbell Brain and Spine, Indianapolis, IN, USA.

Chirag D Gandhi (CD)

Department of Neurosurgery and Neurology, Westchester Medical Center at New York Medical College, Valhalla, NY, USA.

Fawaz Al-Mufti (F)

Department of Neurosurgery and Neurology, Westchester Medical Center at New York Medical College, Valhalla, NY, USA. Electronic address: fawaz.al-mufti@wmchealth.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH